Kiadis announces new data related to its K-NK cell therapy platform presented today at the ISCT Annual Meeting
May 28, 2020 02:35 ET
|
Kiadis Pharma N.V.
Data presented demonstrates improved ex vivo PM21 expansion of NK cells when pre-activated with cytokines. Amsterdam, The Netherlands, May 28, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)...
Kiadis to present at the Jefferies 2020 Healthcare Conference
May 26, 2020 02:30 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, May 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that...
Kiadis Pharma announces abstract accepted for presentation at the 2020 ISCT Annual Meeting
May 25, 2020 02:35 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, May 25, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces an...
Kiadis Pharma kondigt meerdere presentaties over het K-NK-celtherapieplatform voor 25e congres van European Hematology Association
May 14, 2020 09:15 ET
|
Kiadis Pharma N.V.
Amsterdam, 14 mei 2020 - Kiadis Pharma NV ("Kiadis Pharma" of de "Onderneming") (Euronext Amsterdam en Brussel: KDS), een biofarmaceutisch bedrijf gericht op onderzoek in de klinische fase, kondigt...
Kiadis Pharma announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at the 25th Congress of the European Hematology Association
May 14, 2020 09:15 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, May 14, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
Kiadis Pharma kondigt drie presentaties over K-NK-celtherapieplatform op ASCO 2020
May 13, 2020 17:15 ET
|
Kiadis Pharma N.V.
Amsterdam, 13 mei 2020 – Kiadis Pharma N.V. (‘Kiadis Pharma’ of de ‘Onderneming’) (Euronext Amsterdam en Brussel: KDS), gaat drie presentatie houden op de (dit jaar virtuele) bijeenkomst van de...
Kiadis Pharma announces that three abstracts related to its K-NK-cell therapy platform have been accepted at the ASCO 2020 Virtual Annual Meeting
May 13, 2020 17:15 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, May 13, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
Oproep voor de Algemene Vergadering van Aandeelhouders
May 13, 2020 11:45 ET
|
Kiadis Pharma N.V.
Amsterdam, 13 mei 2020 - Kiadis Pharma N.V. ("Kiadis Pharma" of de "Vennootschap") (Euronext Amsterdam en Brussel: KDS), een biofarmaceutisch bedrijf in klinische fase, kondigt aan dat de jaarlijkse...
Notice of Annual General Meeting of Shareholders
May 13, 2020 11:45 ET
|
Kiadis Pharma N.V.
Amsterdam, The Netherlands, 13 May 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that...
Kiadis announces new data validating and enhancing its PM21 K-NK-cell platform presented today at the ASGCT virtual annual meeting
May 12, 2020 06:15 ET
|
Kiadis Pharma N.V.
The first poster presentation (abstract #427) demonstrates similarity between K-NK cells produced with FC21 and PM21The second poster presentation (abstract #765) shows preclinical data with...